Neurogene (NGNE) News Today $15.33 -1.90 (-11.03%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period HC Wainwright Reiterates "Buy" Rating for Neurogene (NASDAQ:NGNE)November 21 at 3:55 AM | americanbankingnews.comPromising Outlook for Neurogene’s Low-Dose NGN-401 Program in Rett SyndromeNovember 20 at 10:19 AM | markets.businessinsider.comNeurogene price target lowered to $45 from $60 at BMO CapitalNovember 20 at 10:19 AM | markets.businessinsider.comNeurogene Inc. Faces Uncertainty with NGN-101 Program Amid FDA Challenges and Strategic HurdlesNovember 20 at 1:09 AM | tipranks.comNeurogene (NASDAQ:NGNE) Earns Outperform Rating from William BlairWilliam Blair reissued an "outperform" rating on shares of Neurogene in a research note on Tuesday.November 19 at 11:45 AM | marketbeat.comNeurogene (NASDAQ:NGNE) Receives "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $55.00 target price on shares of Neurogene in a research note on Tuesday.November 19 at 8:22 AM | marketbeat.comPositive Buy Rating for Neurogene Driven by Promising Low-Dose NGN-401 Results and Proactive Safety MeasuresNovember 18 at 11:37 PM | markets.businessinsider.comNeurogene provides update on NGN-401 clinical trial for Rett syndromeNovember 18 at 11:37 PM | markets.businessinsider.comNeurogene stock plunges 36% on NGN-401 study updateNovember 18 at 11:37 PM | seekingalpha.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNENovember 18 at 7:24 PM | prnewswire.comNeurogene Reports Third Quarter 2024 Financial Results and Highlights Recent UpdatesNovember 18 at 5:25 PM | businesswire.comNeurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett SyndromeNovember 18 at 7:02 AM | businesswire.comNeurogene Inc. (NASDAQ:NGNE) Given Average Recommendation of "Buy" by AnalystsShares of Neurogene Inc. (NASDAQ:NGNE - Get Free Report) have been assigned a consensus rating of "Buy" from the nine brokerages that are covering the stock, MarketBeat reports. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on theNovember 17, 2024 | marketbeat.comNeurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?"Neurogene has been on a huge run in 2024. That came to a halt after the company released trial results. But, the results may be better than the market thinks.November 14, 2024 | marketbeat.comNeurogene (NASDAQ:NGNE) Shares Gap Down After Analyst DowngradeNovember 13, 2024 | americanbankingnews.comNeurogene reports ‘positive’ interim efficacy data from NGN-401 participantsNovember 12, 2024 | markets.businessinsider.comNeurogene Shares Drop 35% on Rett Syndrome Gene Therapy Trial DataNovember 12, 2024 | finance.yahoo.comNeurogene Stock Tanks After Adverse Event In Early-Stage Rett Syndrome Gene Therapy TrialNovember 12, 2024 | benzinga.comLeerink Partners Forecasts Strong Price Appreciation for Neurogene (NASDAQ:NGNE) StockLeerink Partners raised their price objective on Neurogene from $45.00 to $72.00 and gave the stock an "outperform" rating in a research report on Tuesday.November 12, 2024 | marketbeat.comNeurogene (NASDAQ:NGNE) Price Target Raised to $55.00 at HC WainwrightHC Wainwright increased their price objective on shares of Neurogene from $49.00 to $55.00 and gave the stock a "buy" rating in a research note on Tuesday.November 12, 2024 | marketbeat.comRobert W. Baird Increases Neurogene (NASDAQ:NGNE) Price Target to $72.00Robert W. Baird boosted their price target on Neurogene from $54.00 to $72.00 and gave the stock an "outperform" rating in a report on Tuesday.November 12, 2024 | marketbeat.comNeurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett SyndromeNovember 11, 2024 | businesswire.comNeurogene (NASDAQ:NGNE) Hits New 52-Week High - Should You Buy?Neurogene (NASDAQ:NGNE) Reaches New 12-Month High - Here's WhyNovember 11, 2024 | marketbeat.comNeurogene: Interesting CNS Disease Company, Data Coming SoonNovember 10, 2024 | seekingalpha.comFY2024 EPS Estimates for Neurogene Boosted by AnalystNeurogene Inc. (NASDAQ:NGNE - Free Report) - Equities researchers at Leerink Partnrs lifted their FY2024 earnings estimates for Neurogene in a note issued to investors on Monday, November 4th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($4.40) per share for theNovember 7, 2024 | marketbeat.comNeurogene (NASDAQ:NGNE) Stock Quotes, Forecast and News SummaryNovember 6, 2024 | benzinga.comNeurogene (NASDAQ:NGNE) Sees Strong Trading Volume - Should You Buy?Neurogene (NASDAQ:NGNE) Sees Strong Trading Volume - Still a Buy?November 5, 2024 | marketbeat.comNeurogene Secures $200M for Genetic Therapy DevelopmentNovember 5, 2024 | markets.businessinsider.comNeurogene (NASDAQ:NGNE) Stock, Option ChainNovember 5, 2024 | benzinga.comLe titre NGNE atteint un sommet de 52 semaines à 56,17$, porté par une forte croissanceNovember 4, 2024 | fr.investing.comNeurogene obtient 200 millions de dollars de financement PIPE sursouscritNovember 4, 2024 | fr.investing.comNeurogene Announces Oversubscribed $200 Million Private PlacementNovember 4, 2024 | finance.yahoo.comNeurogene (NASDAQ:NGNE) Hits New 1-Year High - Here's WhyNeurogene (NASDAQ:NGNE) Hits New 12-Month High - Here's What HappenedNovember 4, 2024 | marketbeat.comNeurogene (NASDAQ:NGNE) Trading Down 3.7% - Here's What HappenedNeurogene (NASDAQ:NGNE) Trading Down 3.7% - Time to Sell?October 28, 2024 | marketbeat.comShort Interest in Neurogene Inc. (NASDAQ:NGNE) Drops By 50.8%Neurogene Inc. (NASDAQ:NGNE - Get Free Report) was the recipient of a large drop in short interest in the month of October. As of October 15th, there was short interest totalling 934,600 shares, a drop of 50.8% from the September 30th total of 1,900,000 shares. Based on an average trading volume of 113,300 shares, the short-interest ratio is currently 8.2 days. Approximately 9.1% of the shares of the stock are short sold.October 26, 2024 | marketbeat.comPromising Therapeutic Potential of Neurogene’s NGN-401 in Treating Rett Syndrome Drives Buy RatingOctober 23, 2024 | markets.businessinsider.comNeurogene Inc. (NASDAQ:NGNE) Receives Consensus Rating of "Buy" from BrokeragesShares of Neurogene Inc. (NASDAQ:NGNE - Get Free Report) have been assigned an average rating of "Buy" from the nine analysts that are currently covering the company, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation and one has issued a stronOctober 23, 2024 | marketbeat.comNeurogene (NASDAQ:NGNE) Trading Down 4.4% - Here's WhyNeurogene (NASDAQ:NGNE) Shares Down 4.4% - Here's WhyOctober 22, 2024 | marketbeat.comPromising Investment Opportunity in Neurogene: Positive Developments in Rett Syndrome Treatment with NGN-401October 17, 2024 | markets.businessinsider.comL'action Neurogene reste stable selon BMO CapitalOctober 16, 2024 | fr.investing.comNeurogene (NASDAQ:NGNE) Reaches New 12-Month High - Still a Buy?Neurogene (NASDAQ:NGNE) Hits New 12-Month High - Time to Buy?October 16, 2024 | marketbeat.comLe titre NGNE atteint un sommet de 52 semaines à 53,2$, porté par une forte croissanceOctober 16, 2024 | fr.investing.comMarshall Wace LLP Purchases 11,229 Shares of Neurogene Inc. (NASDAQ:NGNE)Marshall Wace LLP lifted its holdings in Neurogene Inc. (NASDAQ:NGNE - Free Report) by 37.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 41,447 shares of the company's stock after purchasing an additional 11,229 shareOctober 6, 2024 | marketbeat.comNeurogene (NASDAQ:NGNE) Trading Up 4.2%Neurogene (NASDAQ:NGNE) Trading 4.2% HigherOctober 3, 2024 | marketbeat.comNeurogene (NASDAQ:NGNE) Stock Price Down 3.4%Neurogene (NASDAQ:NGNE) Trading Down 3.4%October 2, 2024 | marketbeat.comNeurogene (NASDAQ:NGNE) Sees Large Volume IncreaseNeurogene (NASDAQ:NGNE) Sees Strong Trading VolumeOctober 1, 2024 | marketbeat.comNeurogene Inc. (NASDAQ:NGNE) Stake Raised by Driehaus Capital Management LLCDriehaus Capital Management LLC grew its holdings in shares of Neurogene Inc. (NASDAQ:NGNE - Free Report) by 123.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 102,187 shares of the company's sSeptember 30, 2024 | marketbeat.comRhumbline Advisers Invests $491,000 in Neurogene Inc. (NASDAQ:NGNE)Rhumbline Advisers acquired a new stake in shares of Neurogene Inc. (NASDAQ:NGNE - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 13,489 shares of the company's stock, valued at approximately $491,000. RSeptember 26, 2024 | marketbeat.comNeurogene (NASDAQ:NGNE) Trading Up 8.2%Neurogene (NASDAQ:NGNE) Shares Up 8.2%September 25, 2024 | marketbeat.com70,000 Shares in Neurogene Inc. (NASDAQ:NGNE) Purchased by Integral Health Asset Management LLCIntegral Health Asset Management LLC acquired a new position in shares of Neurogene Inc. (NASDAQ:NGNE - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 70,000 shares of the coSeptember 23, 2024 | marketbeat.com Get Neurogene News Delivered to You Automatically Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics… Get Your Free Gold Guide NGNE Media Mentions By Week NGNE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NGNE News Sentiment▼0.310.45▲Average Medical News Sentiment NGNE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NGNE Articles This Week▼172▲NGNE Articles Average Week Get Neurogene News Delivered to You Automatically Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CRON News PLRX News PRTA News REPL News ERAS News AUTL News CGEM News CRGX News AVXL News TRDA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NGNE) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurogene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NGNE Stock Alerts